Mitoconix Bio For Profit
Mitoconix Bio Overview Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases. The companys lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction.
Founded Date:
2016-01-01
Total Funding:
$54.2M
Technology:
Neuropharmacology
Last Funding Type:
Venture - Series Unknown
Investors Number:
6
Industry:
NeuroTech
Headquarters:
Jerusalem, Yerushalayim, Israel
Estimated Revenue:
$6 Million